Unimed to market Searle Maxaquin antibiotic effective March 1.
Executive Summary
SEARLE MAXAQUIN RIGHTS GRANTED TO UNIMED under a marketing and distribution agreement between the two companies that will be effective March 1. Unimed will acquire U.S. marketing and distribution rights to the fluoroquinolone anti-infective in exchange for sales-based distribution fee payments. Searle, which had marketed Maxaquin (lomefloxacin) since its 1992 approval, will continue to manufacture the drug for Unimed.